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Abstract
Many biological responses to intra- and extracellular stimuli are regulated through complex networks of transient protein
interactions where a globular domain in one protein recognizes a linear peptide from another, creating a relatively small
contact interface. These peptide stretches are often found in unstructured regions of proteins, and contain a consensus
motif complementary to the interaction surface displayed by their binding partners. While most current methods for the de
novo discovery of such motifs exploit their tendency to occur in disordered regions, our work here focuses on another
observation: upon binding to their partner domain, motifs adopt a well-defined structure. Indeed, through the analysis of all
peptide-mediated interactions of known high-resolution three-dimensional (3D) structure, we found that the structure of
the peptide may be as characteristic as the consensus motif, and help identify target peptides even though they do not
match the established patterns. Our analyses of the structural features of known motifs reveal that they tend to have a
particular stretched and elongated structure, unlike most other peptides of the same length. Accordingly, we have
implemented a strategy based on a Support Vector Machine that uses this features, along with other structure-encoded
information about binding interfaces, to search the set of protein interactions of known 3D structure and to identify
unnoticed peptide-mediated interactions among them. We have also derived consensus patterns for these interactions,
whenever enough information was available, and compared our results with established linear motif patterns and their
binding domains. Finally, to cross-validate our identification strategy, we scanned interactome networks from four model
organisms with our newly derived patterns to see if any of them occurred more often than expected. Indeed, we found
significant over-representations for 64 domain-motif interactions, 46 of which had not been described before, involving
over 6,000 interactions in total for which we could suggest the molecular details determining the binding.
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Introduction
Proteins are key players in all aspects of cellular life. They
seldom act alone, but rather in combination with other molecules.
Some proteins form parts of large macromolecular complexes that
execute core functionalities of the cell, while others transmit
information in signalling networks to co-ordinate these processes.
To disentangle the complex network of protein interactions, both
complex membership and binary interactions are currently being
studied in large-scale experiments in several model organisms [1–6].
However, interaction discovery data mostly offers information on
whether two proteins do or do not interact, but it cannot provide
details on the mode of binding or the interaction interface. Atomic
details of protein-protein interactions are only available in high-
resolution 3-dimensional (3D) structures, which are collected in the
Protein Data Bank (PDB) [7]. A detailed description of the atomic
contacts involved in interaction interfaces often revealsthe forces that
hold two proteins together, and permits to extract conclusions on the
potential disruptibility of the interface through, for instance, the
action of specific drugs [8]. Recently, the combination of structural
data and assignment of globular protein domains has allowed to
distinguish between two main classes of protein-protein interfaces [9]:
Domain-domain interfaces tend to be large and stable, while
interfaces between a globular domain and a peptide stretch are
usually smaller, sometimes with only a handful of key residues
involved in the binding event [10,11]. The latter type of interface
allows for transient binding, making them ideal for signalling
networks. The classification of interfaces into domain-domain or
domain-peptide gives information on their size, strength, shape, and
other features that may help us understand the interaction between
the two proteins and how it reacts to competitors [12], their correct
identification being thus critical. In both cases, high-resolution 3D
structures provide crucial information on how proteins involved in
these interactions recognize each other and achieve a high degree of
specificity, which in the case of domain-peptide interactions also
includes its context [11]. Furthermore, structures can also help
identify key residues in binding pockets [13] or be used as the base of
complex models for the prediction of domain-motif interactions
(DMIs) [14]. It is thus clear that, the more high-resolution structural
details we can compile on DMIs, the better we will understand their
function and fast evolving profiles.
PLoS Computational Biology | www.ploscompbiol.org 1 May 2010 | Volume 6 | Issue 5 | e1000789The peptides involved in DMIs are characterised by a consensus
motif with specific conserved residues that are recognised by the
binding domain. Some positions of such motifs are restricted to
particular amino acids, while others may allow a set of similar
residues, or even arbitrary ones. Consensus motifs are often given
as regular expressions. For example, the Src-homology-3 (SH3)
domain binds proline-rich peptides, and several variants of the
PxxP (‘x’ or ‘.’ denote arbitrary positions) pattern have been
observed, including [RKY]xxPxxP (class I; square brackets denote
the set of possible residues for this position) and PxxPx[KR] (class
II) [15]. Structurally, linear motifs are frequently found in
disordered regions [16], thus exposed to potential binding partners
and with the ability to adopt a variety of conformations [17,18].
Most motifs assume a well-defined structure upon binding to their
recognition domain, like the polyproline type II (PPII) helix
adopted by SH3-binding peptides [15], the alpha helix, formed by
Nuclear Receptor cofactor peptides [19] or the beta strand in
peptides that interact through beta strand addition, as do PCNA-
and PDZ-binding peptides [20]. Unstructured regions may adopt
different conformations depending on the interaction partner, so
that a given peptide could potentially bind more than one domain,
each with the appropriate structure [21]. Given the small number
of key residues, motifs can arise and vanish spontaneously with
only a few mutations. Along with the modularity of their binding
domains [18,22], this allows a rapid evolution to explore novel
regulatory interactions relatively easily [23]. In this way, a motif
that mediates a particular function or interaction can arise
convergently in otherwise unrelated proteins. Due to their
transient nature, DMIs are difficult to identify in high-throughput
interaction detection experiments [22]. In the last years, several
methods have been developed for de novo discovery of motifs from
sets of sequences assumed to share a feature that e.g. explains
interaction with a common partner [24] or other biological factors
like co-localisation or particular post-translational modifications
[25]. These methods exploit the convergent evolution of linear
motifs in looking for patterns that are over-represented among
unrelated sequences in the query set. Homologous proteins or
regions are removed before the computation of over-represented
motifs, and domains or other well-structured regions are often
masked because motifs tend to occur in unstructured regions [16].
Sometimes, though not always, the motif-binding domain can be
identified in these de novo procedures for motif discovery [24]. A
problem of these sequence-based motif discovery algorithms is the
poor signal-to-noise ratio of many datasets [26,27]. Focusing on
the local environment of the motif, i.e., the flanking regions or context,
increases the sensitivity of these methods [26] and may provide
additional information in the search for functional interpretations
of the novel motifs [27]. However, a potential caveat of methods
relying on evolutionary conservation is that they might well miss
some of the instances that have arisen very recently [26].
Despite the small size of their binding interfaces, domain-motif
interactions are known to be highly specific in vivo [28], although
they can also show some promiscuity, with similar affinities for
native and non-native interaction partners, when tested in
isolation [29]. Depending on the given binding domain, cell type
and organism, the specificity may be encoded primarily in the
motif sequence [13,30], the flanking regions [11], or the network
context [31]; probably these factors often work in concert.
Traditionally, motif recognition patterns were split by one or
two key residues (cf. [32]), but recent work has revealed that a
much finer subdivision may be needed [33] or that, at least for
some domains, there may not even be clear borders between the
recognition profiles of different members of a domain family, but
that recognition profiles cover the whole specificity space instead
[28]. With their high specificity, regulatory function and small
interface, DMIs make excellent candidates for drug targets
[8,34,35], and information about high-resolution 3D structures
of the interfaces may be crucial in this context [21,36]. A recently
published method by Petsalaki et al. [37] searches the surfaces of
3D stuctures for sites that may bind a given motif, based on
physicochemical properties. If the binding domain or a set of
possible binding domains for a motif are known, this tool could
help identify the interface between peptide and domain. A
successful prediction of the binding site on the domain would
reveal much detail beyond what is given by sequence-based
approaches, yet it would not provide the atomic contacts of the
interaction. There are other computational tools, such as iSPOT
[38,39], that have been designed to predict peptide-binding
specificities using also 3D structure information. In this case,
however, one needs to know in advance that a given interaction is
peptide-mediated and which are the exact residues participating in
the interface.
While many current methods for the de novo discovery of motifs
exploit the fact that they tend to occur in disordered regions, our
work here focuses on another observation: upon binding to the
domain, motifs adopt a well-defined structure (see also [40]).
Indeed, the structure of the peptide may be as characteristic as the
consensus motif, and help identify peptides even though they do
not match the established consensus. An example is the linker
peptide between the SH2 and kinase domains in the Src kinase
[41], which adopts a PPII helix and is bound by the SH3 domain
although it does not contain a PxxP motif. The interaction
topology of the linker binding the SH3 domain is the same as that
of intermolecular SH3-peptide pairs, so we consider them to
belong to the same interaction type [42]. Domains may bind different
kinds of peptides in different orientations [43]. During visual
inspection of candidates for DMI based on experimentally
confirmed motifs stored in the Eukaryotic Linear Motifs database
(ELM) [32], we observed that there are several peptide-mediated
interactions in structure which did not match the established
consensus motifs of their corresponding interaction types and
Author Summary
Protein-protein interactions are paramount in any aspect
of the cellular life. Some proteins form large macromolec-
ular complexes that execute core functionalities of the cell,
while others transmit information in signalling networks to
co-ordinate these processes. The latter type, of more
transient nature, often occurs through the recognition of a
small linear sequence motif in one protein by a specialized
globular domain in the other. These peptide stretches
often contain a consensus pattern complementary to the
interaction surface displayed by their binding partners,
and adopt a well-defined structure upon binding. Infor-
mation that is currently available only from high-resolution
three-dimensional (3D) structures, and that can be as
characteristic as the consensus motif itself. In this
manuscript, we present a strategy to identify novel
domain-motif interactions (DMIs) among the set of protein
complexes of known 3D structures, which provides
information on the consensus motif and binding domain
and also allows ready identification of the key interacting
residues. A detailed knowledge of the interface is critical to
plan further functional studies and for the development of
interfering elements, be it drug-like compounds or novel
engineered binding proteins or peptides. The small
interfaces typical for DMIs make them interesting candi-
dates for all these applications.
Domain-Motif Interactions on 3D Structures
PLoS Computational Biology | www.ploscompbiol.org 2 May 2010 | Volume 6 | Issue 5 | e1000789therefore could not be found by a procedure based on known
patterns [11]. Furthermore, we noted that linear motifs have a
particular stretched and elongated structure unlike most other
peptides of the same length. We thus need to, somehow, use this
information to identify more instances of DMIs in the databases,
and derive the consensus binding patterns governing them. This
would provide molecular details for many protein interactions
discovered in high-throughput initiatives, and suggest the relevant
mutagenesis experiments to tinker with them. In this manuscript
we describe our studies of the structural features of known motifs,
and use the results, along with other structure-encoded informa-
tion about interactions, to scan through the set of protein
complexes of known 3D structure in order to identify unnoticed
peptide-mediated interactions among them. We compare our
results with established linear motif patterns and their binding
domains as described in ELM [11], and with other sources of
structural descriptions of peptide-mediated interactions. Finally,
we cross-validate our newly derived patterns on interactome data,
and present a list of novel peptide-binding domains, along with
their respective high-resolution 3D structures and consensus
motifs.
Results
Structural parameters to capture linear motifs
To exploit structural features of peptides and domain-motif
interactions, we first need to establish which parameters are
suitable for the separation of known linear motifs from other,
presumably non-functional peptides of the same length. We thus
selected several structural parameters and applied them to the 631
DMIs of known 3D structure identified in our previous study [11],
to test whether they could capture structural properties of
functional linear motifs. To ensure that these parameters could
partition peptides into true motifs and random cases, we created a
control dataset based on the Structural Classification of Proteins
(SCOP) [44]. For each SCOP fold, we chose one representative
structure and generated all possible peptides of length 4–20
residues, which corresponds to the range of motif lengths in ELM.
Although we cannot guarantee that SCOP folds do not contain
true linear motifs, it is unlikely as they form well-defined tertiary
structures, whereas motifs often occur in unstructured regions and
outside domains. Therefore we assume that the SCOP control set
constitutes a reasonable collection of negative instances for the
identification of linear motifs.
The main structural parameters we developed for motifs are
linearity and elongation (Fig. 1a). The linearity of a peptide is a marker
of how ‘‘flat’’ it is, how much it deviates from a straight line
through the first and last residue. The elongation indicates how long
a peptide extends in space (Fig. 1a; for details see Methods).
Together, linearity and elongation should capture our observa-
tions described above, namely that linear motifs are more flat and
stretched than other peptides. Because flexibility and length of a
peptide increase with the number of residues, it is important to
only compare peptides with the same length in residues. We
computed linearity and elongation for the known DMIs and the
SCOP control set and found that, individually, neither of these
parameters showed sufficient difference between the known cases
and the SCOP control set, although there was a trend for known
DMIs to be longer and more linear than other peptides of the
same length in residues, confirming our observations (Figures
S1a,b). We also assigned secondary structure to the peptides using
DSSP [45] and observed that the distributions of values for
linearity and elongation differed strongly between the classes of
secondary structure. Helical structures were shorter and less linear,
while beta sheets and unstructured regions were more linear and
longer (Figures S1c,d). However, again the differences were not
clear enough to use them to separate known DMIs from other
peptides. Note that, as described above, some linear motifs act
through beta strand addition, and yet others are known to form
alpha helices, though most are found in unstructured regions.
Since no single parameter was able to divide known DMIs from
other peptides, we combined them to see if the trends described
above would give a synergistic effect. For pure geometric
considerations, a peptide that is flat should also be elongated in
comparison to one that is helical or has bends and turns. Indeed,
we found that known motifs fell into distinct regions of the space
spanned by elongation and linearity, and are further subdivided by
classes of secondary structure (Fig. 1b). Thus we concluded that
these three factors can be used to separate structures similar to
known motifs from other peptides of the same length in residues.
Based on these findings, we set out to exploit structural data to find
new instances of peptide-mediated interactions among the over
50,000 high-resolution 3D structures stored in the PDB (Fig. 2).
However, the SVM will only recognise structural features of the
peptide, but not consider any interactions to surrounding domains.
Yet we cannot recognise DMIs based on the peptide alone, we
need to take the interaction environment into account. We trained
a support vector machine (SVM) with the data for linearity,
elongation, secondary structure, accessibility and length in residues
for all the known DMI peptides, and for a random set of 10,000
SCOP control set peptides (for details see Methods). Our first
parameter that takes the environment of the peptide into account,
accessibility, is required because peptides need to be accessible by
other proteins in order to mediate interactions. Additional filters
concerning the interaction environment will be described in the
following paragraphs.
We generated all possible peptides of lengths 4–20 residues from
52,903 3D structures, excluding regions covered by domains as
assigned by Pfam HMMs [46] because motifs are rarely found in
these. Note that this creates many overlapping peptides (cf. Fig. 2),
which we generate in order to find the largest peptide that is
accepted as linear and elongated enough. From the 60,123,359
candidates, only 10,596,512 (18%) peptides in 41,224 structures
were accepted by the SVM. Next they were filtered for contacts to
neighbouring domains in order to find putative domain-peptide
interactions. We intended to identify all peptide-domain interac-
tions, regardless of whether they appear within or between proteins.
Therefore, for each candidate peptide that had been accepted by
the SVM, we checked for contacts with domains in the vicinity,
independent of whether they are part of the same protein or of
another. We did not find enough contacts for 2,890,451 peptides
(details see Methods), meaning that 7,706,061 peptides (73% of the
accepted peptides; percentages in the motif discovery pipeline will
always refer to the previous number of peptides or DMIs) in 40,199
structures remained. Next we removed some of the overlap that
arises due to the way peptides are generated: If a short peptide has
been accepted by SVM and domain contacts, and a longer peptide
that includes the short one has been accepted as well, we only keep
the long peptide (Fig. 3). Note that there may still be partially
overlapping peptides in the set, in cases where none of the peptides
covers the other completely. This overlap will be addressed later, as
we cannot simply join peptides unless the resulting, encompassing
peptide is also accepted by the SVM which tests for the typical
structural features – linearity and elongation – of linear motifs. After
the removal of completely overlapping peptides, we end up with
538,689 peptides (7%) in 40,199 structures, which are involved in
782,430 interactions, since one peptide may interact with several
domains.
Domain-Motif Interactions on 3D Structures
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At this step, we noticed that most of the DMI candidates
corresponded to intrachain interactions (80%) and, upon visual
inspection, many did not seem to be functional. These were often
cases in which the domain and putative peptide, while in contact,
had no extended binding surface, but rather protruding side chains
touching each other, such that it was not clear whether this contact
was biological or whether it might be an artifact that arose e.g. due
to crystallization or buffer conditions. Other instances arose
because of domain definitions that did not perfectly match the
structure, in other words, when the Pfam domain assignments did
not fully cover the structural units (folds), so that remaining
elements (single strands or helices) were identified as binding
peptides. Therefore we used domains in the protein structure
classification CATH, which are defined on 3D structures [47], to
filter out 426,464 (55%) intrachain peptide-mediated interaction
candidates that were covered by these domains. Furthermore,
many intrachain interactions were observed between a domain
and a peptide close to the domain’s boundaries. Accordingly, we
removed 87,986 (25% of the remaining) interactions with a
sequential domain-peptide distance below 10 residues. In addition,
we filtered out contacts between proteins that are not listed in the
Protein Quarternary Structure (PQS) database (2%), which
contains presumed biological units of protein structures rather
than the asymmetric units calculated in the structure determina-
tion process. The latter may bare signs of artefacts such as crystal
packing. Also, during visual inspection we observed peptide
candidates suggested to mediate interactions among multihomo-
mers, which did not appear to be functional (visual inspection). As
peptide-mediated interactions are usually heterologous, we
removed cases in which the domain-containing protein and the
peptide-containing protein form a homomer (1.4% of the
candidate DMIs). Note that intrachain DMIs are heterologous
as well, such as the SH3-peptide and SH2-phosphopeptide
interacctions in the Src kinase described above [41], and
structurally of very similar nature as their interchain equivalents
[48].
Besides the key residues that form the consensus pattern, linear
motifs are characterised by the fact that binding of the motif itself
is sufficient to create a functional interaction (e.g., [49]). As we
could not perform computationally expensive studies of binding
energies for all candidate DMIs, we approximated the binding
Figure 1. Linearity and elongation of linear motifs. (A) The Retinoblastoma-associated protein B domain (RB_B)-binding peptide shows the
typical linear and elongated form found in 3D structures of many motifs (PDB ID 1gh6). The concepts of linearity (the maximum deviation of any Ca in
the motif from the line through the first and last Ca) and elongation (the distance between the first and last Ca of a motif) are illustrated in this
structure. (B) A slice of the data used for SVM training: linearity, elongation and secondary structure classification for 7-residue-peptides, with data
from the SCOP background shown as dots and the data for known DMI shown as solid triangles, using one colour per DSSP classification. Panels (C)
to (F) show the distribution of linearity:elongation values for those secondary structure classifications for which we had known 7-residue-peptides
(none, alpha-helix, bend, and turn). These data slices illustrate how known linear motifs fall into distinct regions of the parameter space.
doi:10.1371/journal.pcbi.1000789.g001
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interface with the full interface between the two partners.
Specifically, we required the interface between domain and
peptide to be at least 150A ˚ 2, which holds for over 90% of the
known DMIs (Figure S2a), but may filter out putative interactions
that are due to artefacts. 34,898 (14%) of the candidates had a
Figure 2. Overview of the generation and filtering of motif-like peptides. (Steps 1 and 2) We generated all possible peptides of 4–20 residues
from regions of 3D structures that did not match Pfam domains. (3, 4) For peptides accepted by the SVM trained on linearity and elongation (cf.
Figure 1) we computed whether there were sufficient contacts with domains in the same structure, which may be in the same or in another protein
chain. (5) Peptides that are completely covered by other (longer) peptides are removed, so that the largest accepted peptide represents shorter
candidates binding to the same region. (6) Peptides in intrachain interactions that are part of CATH domains are often artefacts of differences
between structure- and sequence-based domain assignment and are therefore excluded. (7) Peptides in intrachain interactions that are sequentially
directly next to the binding domain are often artefacts and thus removed, though in general peptides close to domains are allowed, as long as they
have a sufficient sequential distance from their binding domain. (8) Exclude candidate DMI in which the interface is smaller than 150 A ˚, or in which the
interface between domain and peptide is less than 50% of the total interface between the proteins.
doi:10.1371/journal.pcbi.1000789.g002
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that the peptide is a key player in the interactions detected in our
procedure, we required the interface between peptide and domain
to cover at least 50% of the total interface between the two
proteins, which is true for 65% of the known DMIs (Figure S2b).
The 50% threshold is intended to reflect our requirement for the
domain-peptide-interface to have a major role in this interaction.
Some peptide-mediated interactions are formed by multiple
domains binding a peptide, e.g. the seven-blade beta-propellers
formed by WD40 domains [50]. In those cases we only required
all domain-peptide interfaces together to make up 50% of the full
interface, and individual domains to contribute roughly equally
(see Methods). Application of this filter removed 212,125 (95% of
the remaining) putative DMIs, so that 10,739 candidates
remained.
Clustering of candidate interactions by sequence and
topology
In order to identify unnoticed DMIs within the PDB, we needed
to classify distinct domain-peptide interfaces and search for regular
shared features among the peptides that explain why they bind the
domain – a consensus motif. Thus, we needed to group the
candidate interactions by topology to separate distinct interaction
interfaces. Furthermore, due to the redundancy among entries in
the PDB, we needed to create non-redundant sets of peptide-
domain interactions. We only attempted to derive a consensus
motif if sufficient non-redundant information was available. Note
that we did not remove such redundancy in previous steps to
capture as many variations of DMIs as possible.
The topological clustering procedure we developed focuses on
the residues forming the interface. We computed the fraction of
shared peptide-binding residues between each pair of domains
from a family, mapping corresponding residues via alignment to
Pfam’s HMM profile for that family (see Fig. 4 and Methods). Next
we clustered the interfaces based on the shared peptide-binding
residues to separate all interactions for this domain into distinct
interfaces. Our method is similar to that by Teyra et al., [51] but
relies on multiple instead of pairwise alignment of the domains. In
total, we found 822 topological clusters or interaction types,
including 547 domains. The largest clusters contain over 700 DMI
instances. Domains with many different peptide-binding topolo-
gies include protein kinases (8), trypsin (14), Pyridine nucleotide-
disulphide oxidoreductase (Pyr_redox_2, 15 topologies), and the
immunoglobulin V-set domain (18). However, note that these
potential ligands have not been examined for significant motifs yet,
so they do not necessarily represent functional DMIs. The
sequence-based clustering, which is independent of the topological
clustering, serves the creation of a sequentially non-redundant set
Figure 3. Joining of partially overlapping peptides for sequence-based clustering. (A) Partially overlapping peptides cannot be represented
by either one, as both may contribute to an interface in ways not covered by the other. Yet to improve the quality of peptide alignments, and to
ensure that motif matches in the overlapping regions (shown in gray) are only counted once for motif support, we need to create a construct that
holds unique, non-overlapping regions of one or more peptides accepted by the SVM and having a sufficient interface with a domain. (B) Thus, for
each continuous stretch of a protein that is covered by one or more peptides, we built a peptide-containing region. (C) These regions are then aligned
to generate non-redundant sets of peptides binding to a given domain, and each motif match in a peptide-containing region only qualifies for motif
support once. The 90% sequence clustering of the DMIs is computed from a combination of the sequence identities of peptide-containing regions
and those of the binding domains.
doi:10.1371/journal.pcbi.1000789.g003
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consensus patterns. It is used to create groups of ‘‘sufficiently
different’’ peptides per domain, to establish which peptides are
different enough to qualify for motif support, for which non-
redundant data is required. Ideally, a set of unrelated sequences
would allow over-represented motifs to be detected easily, as
similarities cannot be due to larger conserved regions. To this end,
first we need to address the issue of partially overlapping peptides
that arises from the way peptides are generated (Fig. 2). A
sequence-based clustering procedure working on the pure
peptides, which are at most 20 residues long, could not detect
small overlaps. If such a small overlap were to contain a motif, it
would then be supported (counted) twice. To avoid these
duplicated counts, we first joined peptide-containing stretches
such that each protein section that was continuously covered by
peptides (i.e. without gaps) was combined into a single region (see
Fig. 3). Then these non-overlapping regions were aligned, and
their pairwise sequence identity was computed. Clustering by
sequence identity was based on combined sequence identity scores
for both domain and peptide (see Methods for further details). In
total, we found 2,490 clusters of 90% sequence identity for the 547
domains, with the largest clusters having over 200 entries. The
immunoglobulin V-set domain shows the greatest sequential
diversity in its ligands (220 clusters), followed by trypsin (108)
and Major Histocompatibility Complex I (105). We are fully aware
that 90% sequence identity is a more stringent threshold than what
is normally used when creating sets of unrelated proteins. Our
reasons to apply such a strict criterion are twofold: we are handling
relatively short peptides, on which alignment does not always work
reliably, and by selecting a lower threshold, such as 25% or 50%,
we would risk getting too different peptides within the same
cluster. In addition, we also need to identify motifs even among
sets of proteins that are relatively similar (i.e. motifs occurring in
the same protein family). Thus the sets of proteins in our clustering
should be considered as non-redundant rather than unrelated.
Nevertheless, we explored the possibility of relaxing the sequence
similarity threshold to 50% in the clustering procedure (data not
shown), and found that, since the clusters are broader and cover
more instances, the number of interaction types with sufficient
non-redundant information to derive significant patterns (see
subsequent paragraph) dropped from 224 to 96.
Deriving consensus motifs
For each topological cluster with at least 3 non-redundant
sequences, we attempted to derive a consensus motif using
SLiMFinder [25]. SLiMFinder identifies convergently evolved
linear motifs in a set of sequences based on their occurrence in
unrelated sequences, and computes a probability of their
significance. It often suggests more than one possible motif,
ranked by their probability of arising by chance. The program
Figure 4. Topological clustering of peptide-mediated interactions. (A) Alignment of BRCA1 C Terminus (BRCT) sequences to the domain’s
HMM profile; interface residues are highlighted. The colour corresponds to the ‘‘rainbow’’ colouring scheme used for the domain visualisation in
panel B. Lowercase letters refer to amino acids that do not match the domain’s profile, - to positions in the profile that do not occur in the given
sequence. (B) Clustering of the interaction topologies, based on shared interface residues. Domains with the same or highly similar topologies are
grouped together. In the structural representation, all three BRCT domains have the same orientation. Note that the BRCT domain usually forms
dimers that bind the peptide, using the interfaces from clusters (3,4,5,6) and (1,2,9), respectively (cf. Figure 5).
doi:10.1371/journal.pcbi.1000789.g004
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motif-containing sequences, in particular which of them are so
closely related that they should be considered a single case of
support for a candidate motif when it is examined for whether
there are enough unrelated proteins matching it. We provided the
90% sequence identity clusters for this purpose, so that only non-
redundant cases are counted for motif support. Among our 822
topological clusters or interaction types, only 224 contained at
least 3 non-redundant sequences. These covered 157 domains,
with up to 13 clusters per domain. In addition to the sequences
and their evolutionary grouping, we included information on
modified residues in the peptides, because some recognition
domains, like SH2 or 14-3-3, specifically bind peptides that have
been post-translationally modified, e.g., by phosphorylation or
methylation [18,52,53]. The domain’s binding groove recognises
the residue with the post-translational modification, so it should be
a crucial element in a consensus motif. We searched all accepted
peptides for modified residues, and if a particular residue was
modified in more than half of the peptides in a cluster, it was
required for the motif. Furthermore, we checked for helical
peptides, which are another special case for pattern derivation, as
helical structures create a regular pattern of residues pointing
towards the domain vs. residues pointing away from it. If over
50% of the peptides in a cluster were helical according to DSSP,
we enabled the helical pattern derivation feature of SLiMFinder,
which takes this particular spacing into account.
For 152 of the interaction types, covering 111 domains, we
found at least one significant motif, and for 96 of these, significant
motifs were found for all topological clusters (interaction types).
The 46 remaining domains did not yield any significant motif,
although 3 or more non-redundant sequences were available for
pattern derivation. As a curiosity, 36 of the interaction types with
significant motifs (31 domains) involved helical peptides, and 20
(18 domains) required at least one modified residue in the pattern.
In total, 5,316 interactions in 3D structures are covered by these
152 interaction types for which we could derive a significant motif,
including 4,202 inter- and 1,114 intra-chain interactions, respec-
tively. However, 16 clusters among 15 domains contained only
intrachain interactions that, upon visual inspection, did not seem
to be functional peptide-mediated interactions and were thus
excluded. In addition, 8 putative DMI interaction types are always
found between proteins that also have a domain-domain interface
(DDI), which presumably is more reliable. Our assumption here is
that if the DMI is functional, it should also occur independent of a
DDI. Hence we modified our method not to accept clusters unless
there are interchain instances, and DMI that appear without a
DDI in the same protein pair. It is interesting to note that only 18
of the 94 domains for which we find significant patterns in the full
dataset are described in ELM. It should be noted though that
ELM does not always provide Pfam domain names and thus the
overlap could be slightly larger and we are just not able to detect it.
Benchmark of the DMIs identification accuracy
To assess the performance of our method in detecting peptide-
mediated interactions and discarding non-functional peptides or
interfaces in the PDB, we created a benchmark set of 631 known
DMIs [11] and 631 random peptides from the SCOP dataset that
do interact with a domain in a different protein (i.e. we only kept
interchain training data) and are not fully covered by a domain.
To ensure that DMIs are recognised by features beyond
similarities among homologous domains and their binding
peptides in the training set, we performed the benchmark in a
leave-one-domain-out fashion, i.e., we removed all peptides binding to
a given domain from the training set, and tested the recovery of
the corresponding interactions and the detection of its consensus
motif using the resulting SVM. For example, in one instance we
left out all SH2-binding peptides (the test set), then re-ran the full
motif discovery pipeline as described above and finally tested how
many of them were rediscovered by the SVM trained on the
remaining, non-SH2-binding peptides (the training set). If a peptide
overlapping in at least 3 positions with a test set peptide was
accepted and a significant pattern for its domain and topological
cluster could be derived using SLiMFinder, the case was classified
as ‘‘positive’’, otherwise (peptide not accepted or non-significant
pattern) as ‘‘negative’’. For known DMIs, we also tested whether
the known consensus motif given in ELM scored significantly using
SLiMSearch [54], which works similarly to SLiMFinder but allows
checking the significance of a predefined motif on a given set of
sequences.
After applying the described procedure, we could automatically
rediscover 423 of the 631 known DMIs interaction types, which
correspond to a sensitivity of 68%. In terms of domains, we
correctly recovered cases for 20 out of the 30 domains, i.e., the
domain-based sensitivity (67%), very similar to that based on
individual cases. Our method did not accept any of the negative
cases from the benchmark, indicating that it is highly specific.
Analyses on the 208 known DMIs that we could not recover
showed that almost half of them (42%) can be explained by the
fact that they are covered by domains and thus never considered
as peptide candidates by our method, while manually curated sets
like ELM and our previous study [11] did not apply such a filter.
Other reasons for non-rediscovered positive cases included
insignificant patterns (21%) or no pattern determined because of
a lack of data (12%), too few contacts between domain and peptide
(8%), and insufficient surface contribution of the domain-peptide
interface (7%), among others. There are three domains for which
the benchmark returns positive results, but no significant pattern is
found when applying our method to the full PDB, which may be
due to differences in the data set size in significance computation.
Note that cases with too few non-redundant sequences were
ignored (i.e., they are not counted as false negatives) for both
negative and positive test cases. As an additional independent
benchmark, we tested how many of the peptide-mediated
interactions from the benchmark set by Petsalaki et al. [37] could
be identified with our approach. In total, we recovered 298 of the
405 DMIs in their set (74%), which is slightly above the 240 cases
(59%) that they correctly predicted from their benchmark.
Analysis of the results showed that half of the instances that we
missed are due to a low surface contribution, while the other half
was covered by domains or not accepted by our SVM.
Cross-validation with interactome networks
To assess the validity of each motif derived by SLiMFinder and
confirm that it could indeed occur in different protein interactions,
we checked whether it was over-represented in proteins known to
interact with a partner that contains the respective binding domain
(see Methods). For example, although motifs tend to be degener-
ated, 50 of the 593 (8.4%) human proteins that interact with other
proteins containing 14-3-3 domains match the ELM pattern
R[SFYW].S.P, but the number is reduced to only 206 out of the
7215 (2.8%) of the proteins not interacting with any 14-3-3-
containing protein. This corresponds to an enrichment factor of
2.57, which is statistically significant (p-value 2.827e-10, one-sided
Fisher’s exact test). We used interactome data for selected model
organisms with relatively good coverage (yeast, worm, fly, human).
We only tested motifs binding to domains of which a structure was
solved in this species, to make sure that there is a functional
occurrence of it in the species in question, so this validation
Domain-Motif Interactions on 3D Structures
PLoS Computational Biology | www.ploscompbiol.org 8 May 2010 | Volume 6 | Issue 5 | e1000789procedure was limited to 64 domains among the 111 for which we
suggest binding motifs. To avoid false positive hits, we required
pattern matches be outside of globular domains, as do many
sequence-based tools for motif detection [24,25]. In addition, we
only counted those motif-containing proteins as support for the
DMIs if the interaction cannot be explained by a domain-domain
interaction between that protein pair [10]. For each domain, we
tested all patterns derived by SLiMFinder with the given
parameters (see Methods) that is found in one of the selected
interactomes. We then computed whether proteins interacting
with a partner containing the recognition domain are enriched in
hits for the derived motif (one-sided Fisher’s exact test, p-value
threshold 0.025). We found significant enrichments for 64/90 of
the interaction types and 46/64 of the domains, with 1 to 6
patterns per interaction type enriched. Fig. 5 shows structures for
each interaction type found to be enriched in the interactome
cross-validation along with its most significantly enriched motif,
which is not necessarily the top-ranked by SLiMFinder. Across the
interactomes of the four model species considered in this cross-
validation, our DMIs described here could offer molecular bases
for over 6,000 interactions: 5199 in human, 160 in fly, 19 in worm
and 941 interactions in yeast. Applying the statistical test to the 44
known ELM motifs for which we found a 3D structure [11] reveals
significant enrichment for 72% of the DMIs and 74% of the
domains, which is slightly higher than that observed for the
patterns derived in this work. Looking at all 66 ELMs we
considered for our previous study (i.e., also including ELM
patterns for which we did not find occurrences in 3D structure), we
find significant enrichments for 55% of the DMI and 59% of the
binding domains. This decrease might suggest that motifs with
known 3D structures are somehow better defined. Table 1 shows
the list of DMIs for which we found a significant enrichment in the
interactome networks, together with the best-ranked pattern
according to SLiMFinder and the most significantly enriched.
The complete list of patterns is provided in Table S1.
A look at specific examples
Although it is the general trends that conform the main message
of this work, it is always illustrative to look at some specific
examples to understand the nature of our results. Among the novel
DMIs identified by our approach there are two that, in the
meantime, have been included in ELM, but were not listed when
our training set was built. These can be considered ‘‘blind tests’’,
since neither the SVM nor other filtering parameters were selected
using the information in these domains and peptides. One case is
the BRCA1 C Terminus (BRCT) domain, which forms dimers
that bind a phosphopeptide [55]. The different orientations of the
domain with respect to the peptide are recognised in our
procedure, and two topological clusters are generated (see also
Figure 4). The best-ranked pattern is S..FP; where the S is always
found phosphorylated. The ELM annotation also describes
a phosphorylated S, along with two similar patterns (.S..F
and .S..F.K).
The second DMI from our results that has been added to ELM
is cytoskeleton-associated proteins domain (CAP_GLY), which is
involved in the regulation of microtubules [56]. It recognizes short
D/E-containing peptides; the consensus motif that we derived is
DE.F (or D.{0,1}E.F) while the ELM pattern is a much longer one:
[ED].{0,2}[ED].{0,2}[EDQ].{0,1}[YF]$. ELM contains the addi-
tional information that the peptide is always C-terminal, indicated
by the $ symbol. In our approach we do not try to establish
whether a pattern occurs at one of the termini, because peptides in
3D structures are often truncated, so that what appears to be a
terminus won’t necessarily be one in vivo. In this case, however,
neither the ELM CAP_GLY pattern nor the one we derived is
significantly enriched in proteins interacting with those containing
the domain.
A very interesting example is that of the Bcl-2 protein family,
which is crucial in the regulation of apoptosis and has both pro-
apoptotic and pro-survival members [57,58]. Many of these are
multidomain proteins that contain four conserved Bcl-2 homology
(BH) domains. In addition, some members of the extended family
only contain one of the BH domains, BH3, which forms a helical
peptide that can be bound by multidomain Bcl-2 proteins [59]. As
survival despite pro-apoptotic signals is a problem in many cancer
cells, this family comprises several interesting drug target
candidates. Indeed, a number of small molecule agonists and
antagonists have recently been developed and are currently in
various stages of clinical trials [59], some of which have been
developed based on 3D structures of Bcl-2 and its binding peptide
(the BH3 domain). The family is also listed as a peptide-binding
domain on the Pawson lab web site [60], named BH1-BH2-BH3-
BH4, but a consensus motif for the peptides is not given. The top-
ranked significant motif we identified is L..I[AG]D.[ILV], with the
large hydrophobic residues pointing into the binding groove. Two
other, very similar motifs scored significantly (LR.I.D.[LV] and
R.I[AG]D.[LV]); both also contain the large hydrophobic residues
in the appropriate spacing pattern. Structurally, the peptide is
always helical, so one might consider replacing the arbitrary
positions (.) by anything but proline [ ˆP], because of the helix-
breaking properties of this aminoacid. This restriction is also found
in other motifs, such as ligands of hormone receptors (Hormo-
ne_recep), another all-alpha protein that binds small helical
peptide ligands [19].
Finally, in contrast to the three examples above, we could not
identify a significant motif for Clp protease (CLP_protease),
although sufficient non-redundant sequences were available.
Given that Clp proteases degrade peptides with little sequence
specificity [61], the fact that our approach could not identify a
defined consensus motif should be considered positive for our
method.
Discussion
The identification and correct classification of domain-motif
interactions is a key issue to understand the biophysical principles
governing interactome networks, such as the relationship between
protein-binding domains and the consensus motifs they recognize.
Accordingly, we have presented a method to indentify unnoticed
domain-motif interactions (DMIs) among high-resolution 3D
structures, which not only provides information on the consensus
motif and binding domain, but also allows ready identification of
the key residues on both the motif and the domain side. Applying
this methodology to all currently available 3D structures has
revealed 152 DMIs, 127 of which have not been described
previously. Moreover, 64 of the motifs have been found to be
significantly enriched in proteins interacting with those containing
the respective binding domain. In a leave-one-domain-out benchmark
on the 3D structures of known ELMs [11], our method could
rediscover and compute consensus motifs for 2/3 of the known
cases. In addition, it is very precise as none of the random motif-
domain pairs we tested as negative control cases were accepted. As
far as we know, no other method for de novo motif discovery can
provide such details for a novel DMI. Indeed, few other methods
exploit the information encoded in 3D structures, although the
importance of the 3D structure of motifs and their flanking regions
for functional analysis has recently been highlighted [27]. The
information that a peptide adopts a particular structure in
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PLoS Computational Biology | www.ploscompbiol.org 9 May 2010 | Volume 6 | Issue 5 | e1000789Figure 5. DMIs significantly enriched in the interactomes. Significantly enriched motifs were found for 46 distinct domains (shown in gray;
PCNA_N and PCNA_C are shown in the same structure). Binding peptides are given in a rainbow colour scheme, with the SVM-accepted part in sticks
representation and the consensus motif in surface representation. In most cases, differences between the interaction types for a given domain are
subtle, thus only one is shown in this representative figure. However, for domains that form repeats to bind peptides (Arm, BRCT (cf. Fig. 4 and main
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currently only available from high-resolution 3D structures. While
sequence-based methods for motif discovery have the advantage
that they are applicable to larger datasets, they cannot necessarily
reveal the binding domain of a suggested motif [24], or the atomic
details of the interface. Knowing the interface of an interaction,
however, is critical for functional studies [12] as well as the
development of interfering elements, be it drug-like compounds
[21,36], novel binding proteins [62] or engineered peptides in
synthetic circuits or networks [63,64]. The transient interactions
and small interfaces in DMIs make them interesting candidates for
both applications. With previous large-scale methods, gaining this
knowledge in one step was not possible. Only once a pattern and
its binding domain have been identified, the recently published
method by Petsalaki et al. [37] can be used to search structures of
this domain for surface patches that are complementary to the
pattern, although it has some difficulties with helical and beta-
strand-forming peptides. In addition, without further information,
that method cannot show which residues in the domain interact
with the key residues in the motif, and would thus benefit form a
combined strategy with the approach presented here.
A different issue with the sequence-based quest for motifs is that
the ‘‘shared feature’’ may be too loosely defined. For example,
there are many kinases that phosphorylate [ST] or Y residues, yet
it would not be possible to derive a meaningful motif from the set
of phosphorylated sequences alone. Our method instead focuses
on the atomic interface between peptide and domain, which
includes a concise definition of the environment in which the motif
is bound. This, in turn, ensures that all peptides in one group for
pattern derivation use the same interface, which is a rather strict
definition of ‘‘shared feature’’. An additional advantage is the
direct possibility of visual inspection of the suggested DMIs. The
main bottleneck is the availability of domain-peptide interactions
in 3D structures in large enough numbers and with sufficient
diversity to allow for the derivation of a consensus motif. However,
if this information is available, the results are highly specific and
contain a level of detail that cannot be provided by other
techniques. Furthermore, our method successfully detected helical
peptides or those acting through beta-sheet addition, which
present difficult cases for the other 3D-structure-based method
for DMI interface detection [37]. Yet, while our method
successfully identifies DMIs in helical peptides, we do not fully
exploit the information provided in those structures – for the
peptide to be helical, it should not contain proline residues [65].
However, even though no prolines occur in the sequences,
SLiMFinder cannot determine that this residue is ‘‘forbidden’’
because the amount of information encoded in the sequences used
for training is much too small for such conclusions. Only studies on
all possible sequence variations, such as phage display data, could
allow the derivation of forbidden residues in certain positions.
However, one might consider manually modifying the patterns of
helical peptides to reflect this, by replacing all arbitrary positions (.)
by [ˆP], as it has been done e.g. for the hormone receptor ligands
in ELM (pattern [ˆP](L)[ˆP][ˆP](L)(L)[ˆP], parentheses indicate
that the leucines are key residues).
We chose strict thresholds on contacts and interface size to limit
the occurrence of false positives, which are often problematic when
dealing with so few key residues as in motif-mediated interactions.
While our high precision shows the advantages of those strict
thresholds, we do miss some true motifs as described in ELM, in
particular due to the exclusion of regions assigned to Pfam
domains, which is responsible for almost half of the true motifs we
do not recover. Yet the inclusion of these regions would
disproportionately increase the computation time as well as the
risk of false positives, since it has been shown that motifs usually
occur outside of domains [16]. Nevertheless, it may be possible to
create a fine-tuned version of our method that is able to also detect
motifs located in domains. The fact that we do not find a pattern
for unspecific cleavage sites (e.g. for the Clp proteases) shows that
the method is also capable of separating random peptides from
functional ones at the stage of motif derivation, should random
peptides have been accepted by the SVM. Some motifs that were
only detected in interactions between a peptide and domain in the
same protein (intrachain interaction) could not be confirmed as
true DMIs upon visual inspection and thus, we cannot assume to
derive motifs accurately from intrachain data alone. This issue
may improve if intrachain DMI data would be included in the
training data, which is currently not the case as no reliable
collection of intrachain peptide-mediated interactions is available.
It should also be noted that our final list of DMIs (Table 1 and
Fig. 5) only includes those cases that could be confirmed in the
interactome cross-validation, even though we know that some real
cases, like the cytoskeleton-associated proteins domain
(CAP_GLY) and many other known ELM motifs, are not
significantly enriched in the current interactomes. This issue
may improve with growth of protein interaction databases.
Likewise, newly solved 3D structures may contain new DMIs, or
raise information content for existing ones above the threshold
required for application for our method. We cannot expect to
recover the exact patterns described in ELM, which are manually
curated and often exploit dedicated experiments to the relevance
of a particular position or residue. Yet both our patterns and those
from ELM score significantly in the datasets derived from 3D
structures, and manual comparison shows that they are often
similar. A potential problem is that the motifs we derive can only
take sequences into account that occur in 3D structures, which
may introduce a bias that would not be present in studies on all
possible binding peptides. This might be addressed by applying
methods such as iSPOT on the 3D structures identified here,
combined with data from phage display scans [39]. On the other
hand, we can include information on modified residues and
particular spacing patterns in motif derivation, which are usually
characteristic for a domain family and not just for individual
instances. Recent studies have shown that the binding preferences
of individual domains are probably too complex to be captured in
regular expressions but that more complex models will be required
[14,33]. In addition to the physicochemical binding preferences of
the domain, contextual factors will govern which interactions
happen in vivo and which do not [18,66]. The importance of the
context may vary for different recognition domains and biological
processes; for example, phosphorylation networks appear to
heavily rely on contextual information [31], while a few
(phosphorylation independent) domains have been shown to very
specifically recognise the amino acid sequence of their binding
partners [13,30]. Again, more complex models will probably be
required to integrate all this information that leads to the in vivo
specificity of any given protein. Nevertheless, consensus motifs can
be very helpful in studying commonalities among and differences
text), TPR_1, TRF, WD40), we have visualized all domains required to bind one peptide; these usually employ different interaction types. Blue domain
names indicate those that were described in the ELM training dataset [11], violet names mark additions to ELM since 2007 [32], which were not in our
training set, and green names indicate DMIs that are described on the Pawson lab web site [60] but not in ELM.
doi:10.1371/journal.pcbi.1000789.g005
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Domain TC top-ranked pattern Enrichment p-value most enriched pattern Enrichment p-value
14-3-3 0 [HR]S.P 1.31 0 SHSY 3.63 0.001
14-3-3 2 LDL 1.19 0.007 LD.{0,1}L 1.22 0
R[SFYW].S.P (LIG_14-3-3_1), R.[SYFWTQAD].[ST].[PLM] (LIG_14-3-3_2), [RHK][STALV].[ST].[PESRDIF] (LIG_14-3-3_3)
Arm 0 KK[KR]K 1.45 0.043 KKRK 2.25 0.001
Arm 1 KKRKV 2.13 0.383 K[KR].K[LV][DE] 3.04 0.001
Arm 2 KK[KR]K 1.45 0.043 KKRK 2.25 0.001
Asp 2 HPFH 01 VV.A 2.58 0
Bcl-2 2 QL..I[AG]D 01 R.I[AG]D.[LV] 13.56 0.009
BIR 0 AVP[FI] 8.87 0.107 [IV].[FY][FY].P 25.16 0
Borealin 0 L.EFL 33.95 0 L.EFL 33.95 0
BRCT 0 S..FP.A 1.2 0.501 D..QVF.F 23.55 0.002
BRCT 1 SPTF 2.14 0.116 S.TF 1.56 0.01
Bromodomain 2 [GS].GG 1.36 0 GKG.{0,1}GK 8.8 0
Chromo 2 ARK[ST] 2.27 0.07 T.{0,2}ARKS 9.62 0.003
Cullin 0 WN.V..W.W 86.76 0 W..V..W..DI 86.76 0.012
Cyclin_N 0 K.{0,1}RRL 1.13 0.458 KR.L..E 3.01 0.003
[RK].L.{0,1}[FYLIVMP] (LIG_CYCLIN_1)
DUF618 0 PSYSP 01 PSY.P 56.58 0.001
Dynein_light 0 K.TQT 6.2 0.15 TQT 4.11 0
[KR].TQT (LIG_Dynein_DLC8_1)
FHA 0 EVTE.D 25.86 0.039 LE.TE 5.32 0
T..[ILA] (LIG_FHA_1)
Fibrinogen_C 0 HRP 2.37 0.085 GPR 2.25 0.014
Filamin 0 [KR]S[AS] 1.2 0.066 [ST]..[ST][ST] 1.17 0.021
Focal_AT 0 R.L.E 1.56 0.022 LSE 1.81 0.002
[LV][DE].[LM][LM]..L (LIG_PXL)
Histone 0 Q.RT.Y.F 01 QG.TL.G 40.89 0.001
Hormone_recep 2 [IL]L[HR].LL 0.7 0.806 [IL]L[HR].L 1.36 0.02
L[ˆP]{2}[HI]I[ˆP]{2}[IAV][IL] (LIG_CORNRBOX), [ˆP](L)[ˆP][ˆP](L)(L)[ˆP] (LIG_NRBOX)
IF4E 0 YDR.FL 156.16 0 YDR.FL 156.16 0
IRS 0 [FI]..[KR].[FY] 1.48 0.003 [FI]..[KR].[FY] 1.48 0.003
MAP1_LC3 0 D.WTH.S 108.44 0.009 D..THLS 108.44 0.009
MBT 0 HRK..RD 56.58 0.018 RKV.RD 339.48 0.003
PCNA_C 0 K.{0,2}QATL 34.22 0.029 K.{0,2}Q.T 1.6 0.021
PCNA_N 1 K.{0,2}QATL 34.22 0.029 K.{0,2}Q.T 1.6 0.021
(ˆ{0,3}|Q).[ˆFHWY][ILM][ˆP][ˆFHILVWYP][DHFM][FMY].. (LIG_PCNA)
PDZ 0 RETQV 01 R.ET.V 2.89 0
.[ST].[VIL]$ (LIG_PDZ_1), .[VYF].[VIL]$ (LIG_PDZ_2), .[DE].[IVL] (LIG_PDZ_3)
Peptidase_C14 1 D.SD 1.36 0.028 DE.D 2.18 0
Peptidase_C14 4 DE.D 2.18 0 DEVD 4.1 0
PHD 0 RTKQT 11.52 0.011 A.TK..AR 17.29 0
PID 2 Y.NP.YK 01 GY.N.TY 68.15 0.015
Pkinase 3 RRRHP 1.02 0.675 RR.HPS 4.08 0.015
Pkinase 6 T.NL 1.14 0.024 T.NL 1.14 0.024
Pkinase_Tyr 2 EIF..FE 01 E.FG..E 2.43 0.021
Profilin 0 PPP.{0,1}PP 4.48 0 PPP..P.P 8.6 0
Proteasome_A_N 0 K.EDN.G 01 KEE..L 3.1 0.007
RNA_pol_L 0 T.R..QF..R 32.47 0.031 R.VQF.A 21.64 0.003
SET 0 AR.{0,1}K.T 2.28 0.068 ARKST 20.55 0
SH2 0 YVNV 3.85 0 HIYDE 8.18 0.015
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derivation of motifs is that peptides are always given together with
their binding domain in a way that can easily be transferred to
other sorts of data, which is not always the case for manually
curated DMIs. For example, by matching the pattern in one
sequence and the binding domain in another may explain the
mechanism behind some of the many protein-protein interactions
which are currently being discovered in high-throughput interac-
tion discovery experiments. This, in turn, may make them
amenable to tinkering with this part of the network, either by
designed peptides that might have fine-tuned affinity
and specificity for the binding domain [63,67] or by
drug-like compounds that can interfere with the interaction
[21,34,36], a long-standing dream of the pharmaceutical industry
[35,68,69].
The information we exploit here to identify novel DMIs among
the set of interactions of known 3D structure (i.e. well-defined
structure upon binding), is of different nature than the one used by
more traditional sequence and disorder-based methods applied by
many other tools [24–26]. We think that our approach presents an
extension to the currently available techniques, and should be
regarded as complementary to them. Sequence-based discovery
methods have access to much more data, especially with current
high-throughput interaction and other functional association
studies. The surface-searching method also accesses a larger pool
of data, because more structures of individual domains are
available than of DMI. Yet neither method can provide the level of
detail we access here. The combination of these two kinds of data,
with 3D structures to define motif interfaces and large sequence
databases to establish evolutionary over-represented patterns, will
certainly make a powerful predictor of linear motifs. On a limited
scale, we already created such a hybrid method in the interactome
cross-validation, yet more sophisticated implementations could
include a wider variety of biological data and tackle the problem of
capturing specificity, on the more abstract level of domain families
as well as on the level of individual domains.
Methods
Control dataset
The control data is based on the Structural Classification of
Proteins (SCOP) [44]. For each fold, we chose one representative
Domain TC top-ranked pattern Enrichment p-value most enriched pattern Enrichment p-value
SH2 1 S.TIYA 4.09 0.229 IY.QVQ 8.18 0.015
Y.N. (LIG_SH2_GRB2), Y[IV].[VILP] (LIG_SH2_PTP2), Y[QDEVAIL][DENPYHI][IPVGAHS] (LIG_SH2_SRC), Y..Q (LIG_SH2_STAT3), Y[VLTFIC].. (LIG_SH2_STAT5)
SH3_1 0 P.{0,1}P.{0,2}P.{0,2}P 2.2 0 P.PV.{0,1}PP 9.22 0.019
SH3_1 1 P.{0,1}P..P 1.8 0 P.{0,1}PP.{1,2}P 30
SH3_1 2 DR.TKP 1.72 0.468 DR.T 1.44 0
[RKY]..P..P (LIG_SH3_1), P..P.[KR] (LIG_SH3_2), …[PV]..P (LIG_SH3_3)
SIR2 0 HKKLM 01 [KR][HR].[KR] 1.46 0.008
TPR_1 0 EEVD 2.01 0.027 ME.VD 4.02 0.007
EEVD$ (LIG_TPR)
TRF 0 [FY].L.P[LV] 2.67 0.172 FN.A..GR 244 0.004
Trypsin 1 PG.Y 1.87 0.001 PG.Y 1.87 0.001
Trypsin 3 CGK 0.66 0.925 CG..T 1.86 0.015
Trypsin 5 PAIQP 01 P.IQ 1.59 0.018
Trypsin 7 CT..IPP 01 CT..I.P 8 0.024
Trypsin 11 CG.[KR] 1.24 0.189 CG..T 1.86 0.015
Trypsin 12 [FY]E.IP.E 01 DF..IP.{0,1}E 14.39 0.007
Tyr-DNA_phospho 0 KLNY 177.45 0.006 KLNY 177.45 0.006
V-set 3 Q.DPAF 15.93 0.062 K..[HK].G 1.38 0.008
V-set 10 E.DKW 5.31 0.053 A.FRHD 15.93 0.006
V-set 11 WF..T..LW 01 QE..D..RE 10.62 0.014
V-set 15 D.PDY.S 01 P.Y.S 1.79 0.001
V-set 16 E.DKW 5.31 0.053 L.FGYP 31.87 0.001
VHS 0 D..LL 1.12 0.314 DL..I 1.72 0.012
WD40 0 RTKQT 6.71 0.006 TKQTA 8.39 0.003
F.[IV][ˆWFY][ˆWFY][IL][ILM] (LIG_EH1)
WW 0 P.{0,2}PP.{0,2}P 1.64 0 PPPY 6.24 0
PP.Y (LIG_WW_1), PPLP (LIG_WW_2), …[ST]P. (LIG_WW_4)
List of domains and motif patterns determined in this study and found to be significantly enriched in the interactome cross-validation. The top-ranked SLIMFinder motif
and the pattern with the highest significant enrichment are shown for each topological cluster (TC), along with the respective enrichment and p-values. If available, ELM
ligands of the domain are given below the patterns derived in this work. A table with all DMI, including those not enriched in the interactome cross-validation as well as
the 3 top-ranked patterns for all candidate DMIs is given in Table S1.
doi:10.1371/journal.pcbi.1000789.t001
Table 1. Cont.
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length. This dataset contains high overlaps among peptides from
the same structure, which gives us a large variety of possible
structural conformations of peptides to study. For the benchmark,
we masked all peptides in regions covered by Pfam domains [46]
and selected unmasked background peptides that had at least 4
contacts with a domain in a different protein chain as negative
control cases. Thereby we ensured that negative cases had a
chance to be identified as candidate peptides and would not be
removed by our filters on peptides covered by domains and the
minimum number of contacts.
Structural parameters
The Elongation or ‘‘length’’ of a peptide is the distance
between the Ca of the first and last residue of a peptide in
Angstroms (A ˚). Because flexibility increases with peptide length
in residues, short peptides have a small range of possible
elongation values, while it varies more for long peptides. The
Linearity is computed by constructing a line through the first and
last Ca of each peptide, then calculating the distance of each Ca
in the peptide to this line, and returning the maximum distance.
A low value indicates a very flat or linear peptide. We used
DSSP [45] for secondary structure a s s i g n m e n t st op e p t i d e sf r o mt h e
set of known DMI and from the SCOP background. The
assignment is done on a single protein, after removing other
chains in the structure but before extraction of the peptides, as
DSSP does not always perform well on small fragments. Each
peptide is assigned the DSSP class most frequently found among
its residues. Note that because SVMs work on numerical data,
including a more detailed description of the secondary structure
of a peptide, such as the order of DSSP classifications, would
require a much more complex model. We also used accessibility
data computed by DSSP, and assigned the average accessibility
of its residues to each peptide.
Training of the Support Vector Machine (SVM)
We used the implementation ‘‘SVM-light’’ [70] and trained it
on our data with a cost-factor of 10, meaning that errors in the
classification of positive cases are 10 times worse than errors in the
classification of negative cases, a trade-off between training error
and margin of 0.1, and a linear kernel. These parameters were
selected after searching the parameter space for different
combinations of values for cost-factor, trade-off and kernel
function, and testing recovery of known positive and negative
(SCOP control set) cases. The estimation of classification errors
also takes the fact that our set of positive cases is much smaller
than the negative set into consideration.
Interactions with neighbouring domains
To form a DMI, each peptide accepted by the SVM was also
required to interact with a nearby domain, which may be part of
the same protein or of another. Linear motifs usually form one
connected interface with their binding domain, thus we excluded
peptides in which there was a region of more than 4 residues that
did not contact the domain, as well as those cases in which less
than 60% of the peptide residues made contact with the domain.
Interface size and ratio
We used NACCESS [71] to compute the interface between
domain and peptide, and the ‘‘full interface’’ between the
domain-containing protein and the peptide-containing protein
(interchain DMIs) or between the domain and the rest of the
protein (intrachain DMIs). In general, to accept a peptide-
mediated interaction, the domain-peptide interface has to
constitute at least 50% of the full interface. To accommodate
for different stoichiometries in domain-peptide interactions
(multiple domains binding one peptide), the threshold for the
interface ratio was set to 0.5/N, where N is the number of
domains involved in the interaction. If domains do not contribute
roughly equally to an interaction or, more exactly, if any domain
contributes less than N/0.5, they are removed in a filtering step.
Since this changes the number of domains involved in the
putative DMI and hence the minimum interface size, we repeated
the filtering until each domain-peptide interface contributed
appropriately for its stoichiometry and no domain was removed
any more in the given step; in other words, we repeated the
procedure until convergence. Note that, while all domain-
peptide-interfaces have to contribute at least 0.5/N,t h e yd on o t
necessarily contribute equally.
Clustering by topology
We first aligned all sequences for a given domain to the
corresponding Pfam HMM profile [46]. The aligned positions
are used as a normalized numbering of the sequences, allowing
easy comparison and mapping of corresponding positions. Next
we computed the contacts for each domain-peptide interaction,
and compared for each pair of domains how many of the
corresponding domain positions contacted the peptide in both
cases (cb). The resulting distance score is 1{
2|cb
c1zc2
,w i t hc1 and
c2 being the number of domain positions involved in contacts
for the two respective domains. If the interface sizes are vastly
different (one has more than double the contacts of the other),
we set the score to 1, as these interfaces are considerably
different despite possible overlaps (visual inspection). After
computing the distance matrix for all DMIs involving the given
domain, we clustered the interaction topologies by complete
linkage hierarchical clustering [72] and cut the resulting tree at
a distance of 1, which corresponds to no shared contacts (or
artificially separated cases with large differences in interface
size, cf. above).
Computing peptide regions for overlapping peptides
Each continuous part of a protein that was covered by one or
more peptides was designated as a peptide-containing region.
These regions are non-overlapping by definition, and they
represent parts of the protein that contain one or more peptides
structurally similar to those found in known DMIs. The main
motivation for this was that each pattern match in a given
structure should only be counted once for ‘‘support’’ of that
pattern, independent of how many accepted peptides include it (cf.
Fig. 3).
Clustering by sequence
For the sequence-based clustering, domain and peptide
alignments are computed individually, and then the pairwise
similarities are combined into one score, which is then used for
clustering. For domains, all sequences of a given family are aligned
to the Pfam HMM profile, and the sequence identity is computed
from this alignment, yielding a pairwise domain sequence identity
score sdij for each pair of domains. The corresponding peptide-
containing regions are aligned using the Needleman-Wunsch
algorithm [73], yielding a pairwise peptide sequence identity score
spij for each pair of peptides. The distance score is then computed
as 1{
sdijzspij
2
for each pair ij, where i and j are candidate
domain-peptide interactions. Like for the topological clustering,
Domain-Motif Interactions on 3D Structures
PLoS Computational Biology | www.ploscompbiol.org 14 May 2010 | Volume 6 | Issue 5 | e1000789we applied complete linkage hierarchical clustering [72]. Note that
we use both domain and peptide sequences, because for the
diversity of a DMI it makes a difference whether a given peptide is
always bound by the same domain or by different domains. As a
cut-off here we chose 0.1, which corresponds to 90% sequence
identity. Thus, all resulting clusters have a combined sequence
identity of 90% considering both domains and peptides.
Motif derivation
We used SLiMFinder [25] to derive consensus motifs for the sets
of peptide sequences bound in each topological cluster. We
computed the amino acid frequencies from all sequences in the
PDB, and disabled the ‘termini’ flag because beginnings and ends
of our sequence fragments usually do not correspond to actual
protein termini. ‘‘Unrelated protein clusters’’ (UPCs) were defined
using the sequence-based clustering described above. Only
topological clusters with 3 or more UPCs were searched for
consensus motifs; the information content is too low in the other
cases.
Enrichment of DMIs in interactome networks
We created interactomes for human, fly, worm and yeast by
integrating protein-protein interaction data from the databases
MINT, IntAct and HPRD [74,75,76] that are supported by peer-
reviewed publications. To ensure species specificity, we excluded
hybrid interactions observed between proteins from different
species, resulting in networks with 53,290 (human), 19,260 (fly),
5,566 (worm) and 60,721 (yeast) interactions, respectively. As
described above, we only considered interactions that could not be
explained by domain-domain interactions as observed in 3D
structures [10], which reduces the interactomes to 43,882, 18,113,
5,234 and 58,426 edges, respectively. These interactomes involve
7,808 human, 6,610 fly, 3,111 worm and 5,266 yeast proteins,
respectively.
To calculate motif enrichments in the interactome networks, we
assigned Pfam domains, via HMM profiles, to all proteins in the
respective interactomes, and tested for motif hits by regular
expression pattern matching, only considering regions outside
domains as described above. We then created a contingency table
for each motif and species stating how many proteins contained at
least one motif match, and how many interact with a protein
containing the motif’s binding domain. The enrichment factor was
computed as
pim=pi
pm=p
, where pim is the number of proteins that
interact with another protein know to contain the binding domain
and also have a motif match, pi is the number of proteins that
interact with another containing the binding domain, pm is the
number of proteins with a motif match, and p is the total number
of proteins in the interactome. The p-value was computed using
Fisher’s exact test on the contingency table, as implemented in R
[77].
Supporting Information
Figure S1 Linearity and Elongation of known motifs in
comparison to a background sampling. (a) Linearity, (b) Elonga-
tion, (c) Linearity for 7-residue-peptides, split by DSSP-classifica-
tion, (d) Elongation for 7-residue-peptides, split by DSSP-
classification. The distribution of values varies greatly across and
within classes of secondary structure.
Found at: doi:10.1371/journal.pcbi.1000789.s001 (0.14 MB EPS)
Figure S2 (a) Interface size for known domain-peptide interac-
tions. (b) Ratio of the interface between domain and peptide to the
full protein-protein interface for the known DMI. Both are
computed as described in the Methods section of the main
manuscript.
Found at: doi:10.1371/journal.pcbi.1000789.s002 (0.77 MB EPS)
Table S1 All DMI candidates derived from high-resolution 3D
structures, specifying the binding domain, topology or interaction
type ID, the consensus motif, enrichment and p-value in the
interactome cross-validation, if applicable, and the ELM pattern
and name, if available. For each interaction type, up to 3 top-
ranked motifs are provided.
Found at: doi:10.1371/journal.pcbi.1000789.s003 (0.05 MB XLS)
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